- ►pubget.com [PDF] SN Davis, D Johns, D Maggs, H Xu, JH … - Diabetes Care, 2007 - Am Diabetes Assoc RESEARCH DESIGN AND METHODS— Successful maintenance of glycemic control was
predefined as an A1C increase of <0.5%. A total of 49 patients (aged 53 ± 8
years, with BMI 34 ± 4 kg/m 2 , A1C 8.1 ± 1.1%, and duration of diabetes ... Cited by 31 - Related articles - BL Direct - All 8 versions
JB Buse, DC Klonoff, LL Nielsen, X Guan, … - Clinical therapeutics, 2007 - Elsevier For this interim analysis, data were pooled from patients who completed 1 of
three 30-week, multicenter, double-blind, placebo-controlled trials and their
open-label extensions. In the initial trials, subjects were randomized to ... Cited by 92 - Related articles - All 3 versions
AH Barnett, J Burger, D Johns, R Brodows, … - Clinical therapeutics, 2007 - Elsevier Methods: This multinational, randomized, open-label, crossover noninferiority
study compared the efficacy of exenatide 10 pg BID and insulin glargine QD
(titrated targeting a fasting serum glucose (FSG) level ≤5.6 mmol/L) in ... Cited by 41 - Related articles - All 3 versions
J Rosenstock, V Fonseca - Diabetes Care, 2007 - Am Diabetes Assoc The recent American Diabetes Association/European Association for the Study of
Diabetes consensus treatment algorithm for type 2 diabetes has advanced basal
insulin treatment as a much earlier therapeutic option following a ... Cited by 3 - Related articles - All 6 versions
[CITATION] for the Sitagliptin Study 035 Group. Efficacy and safety of the dipeptidyl peptidase-4 …
MA Nauck, S Duran, D Kim, D Johns, J … - Diabetologia, 2007 - Springer Abstract Aims/hypothesis The aim of this 52-week, open-label, non- inferiority
trial was to compare the safety and efficacy of exenatide (an incretin mimetic)
with that of biphasic insulin aspart. Materials and methods Patients on ... Cited by 134 - Related articles - BL Direct - All 4 versions
- ►annals.org [PDF] B Zinman, BJ Hoogwerf, S Duran Garcia, DR … - Annals of internal medicine, 2007 - Am Coll Physicians Background: Exenatide therapy is effective in combination with metformin or
sulfonylureas for treating type 2 diabetes. Thiazo- lidinediones (TZDs) also are
commonly used, but the efficacy of exenatide with a TZD has not been reported. Cited by 121 - Related articles - BL Direct - All 5 versions
DC Klonoff, JB Buse, LL Nielsen, X Guan, … - Current Medical Research and Opinion®, 2007 - informahealthcare.com Background: Exenatide, an incretin mimetic for adjunctive treatment of type 2
diabetes (T2DM), reduced hemoglobin A1c (A1C) and weight in clinical trials. The
objective of this study was to evaluate the effects of ≥3 years exenatide ... Cited by 93 - Related articles - BL Direct - All 7 versions
H Linnebjerg, PA Kothare, Z Skrivanek, A … - Diabetic Medicine, 2006 - interscience.wiley.com It is also possible that your web browser is not configured or not able to
display style sheets. In this case, although the visual presentation will be
degraded, the site should continue to be functional. We recommend using the ... Cited by 19 - Related articles - BL Direct - All 4 versions
V Fonseca, A Schweizer, D Albrecht, MA … - Diabetologia, 2007 - Springer Abstract Aims/hypothesis Type 2 diabetes is difficult to manage in patients with
a long history of disease requiring insulin therapy. Moreover, addition of most
currently available oral antidiabetic agents increases the risk of ... Cited by 105 - Related articles - BL Direct - All 4 versions
